Adverum Biotechnologies, Inc.

As of September 5, 2025, Adverum Biotechnologies, Inc. is in a mildly bearish trend, with daily moving averages and weekly indicators supporting this outlook, despite some mildly bullish signals from the MACD; the stock has significantly underperformed the S&P 500, with a year-to-date return of -36.83% compared to the index's 12.22%.

As of November 4, 2024, Adverum Biotechnologies, Inc. is considered a risky investment due to its overvaluation indicated by a high Price to Book Value of 2.24, low EV to EBIT of 0.11, negative EV to Sales ratio of -16.73, and significant stock declines of -36.83% year-to-date and -97.62% over five years, contrasting sharply with the S&P 500's performance.

As of November 4, 2024, Adverum Biotechnologies, Inc. is considered a risky investment due to its overvaluation, significant losses reflected in a negative EV to Sales ratio, unfavorable valuation metrics compared to peers, and a year-to-date stock performance of -52.25% against the S&P 500's 2.44% return.

As of June 9, 2025, Adverum Biotechnologies, Inc. shows a mildly bearish trend, with mixed signals from indicators like MACD and RSI, while moving averages and other metrics suggest caution.

As of March 2022, the management team of Adverum Biotechnologies, Inc. includes Patrick Machado (Independent Chairman), Dr. Laurent Fischer (CEO), and several independent directors: Dr. Mehdi Gasmi, Dr. Eric Carter, Ms. Rekha Hemrajani, Dr. Mark Lupher, and Mr. James Scopa. This team provides governance and strategic direction for the company.

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on treating serious ocular and rare diseases. It has a market cap of $48.47 million and reported a net profit loss of $47 million as of March 2025.

As of Jun 18, Adverum Biotechnologies, Inc. has a market capitalization of 48.47 million, with net sales of 1.00 million and a net profit of -133.56 million over the last four quarters. The company reported shareholder's funds of 70.71 million and total assets of 179.84 million as of Dec 24.